Edition:
United Kingdom

Foamix Pharmaceuticals Ltd (FOMX.OQ)

FOMX.OQ on NASDAQ Stock Exchange Global Market

5.19USD
18 Sep 2018
Change (% chg)

$-0.55 (-9.58%)
Prev Close
$5.74
Open
$5.74
Day's High
$5.74
Day's Low
$5.03
Volume
491,096
Avg. Vol
91,185
52-wk High
$7.55
52-wk Low
$4.45

Chart for

About

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and... (more)

Overall

Beta: --
Market Cap(Mil.): $241.40
Shares Outstanding(Mil.): 37.43
Dividend: --
Yield (%): --

Financials

  FOMX.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -1.31 -- --
ROI: -49.58 1.78 14.61
ROE: -49.79 3.29 16.33

Foamix acne drug meets main goals in late-stage trial, shares surge

Foamix Pharmaceuticals Ltd said on Tuesday that its lead drug treating moderate-to-severe acne met the main goals of its third late-stage study, sending its shares up 57 percent in extended trading.

11 Sep 2018

UPDATE 1-Foamix acne drug meets main goals in late-stage trial, shares surge

Sept 11 Foamix Pharmaceuticals Ltd said on Tuesday that its lead drug treating moderate-to-severe acne met the main goals of its third late-stage study, sending its shares up 57 percent in extended trading.

11 Sep 2018

Foamix Pharma's acne drug meets main goals in late-stage trial

Sept 11 Foamix Pharmaceuticals Ltd said on Tuesday that its drug treating moderate-to-severe acne met the main goals of its third late-stage study.

11 Sep 2018

Earnings vs. Estimates